AN/TPY-2 - Mobile, X-band Phased-array Radar Helps Missile Defense Agency

Raytheon Company delivered its eighth AN/TPY-2 radar to the Missile Defense Agency (MDA) in support of the U.S. combatant commands.

An integral capability of the Ballistic Missile Defense System (BMDS), AN/TPY-2 is a mobile, X-band phased-array radar that helps protect the U.S., deployed forces, and America's friends and allies by searching, acquiring and tracking threat ballistic missiles and discriminating between threats and non-threats.

"Delivering the vital AN/TPY-2 helps meet the growing demand for radars that can help defend the U.S. and its allies from the more than 5,500 ballistic missiles MDA estimates are not controlled by the U.S., NATO, Russia or China," said Dave Gulla, vice president of Global Integrated Sensors in Raytheon's Integrated Defense Systems business.

"The AN/TPY-2 has proven itself an indispensable component of our nation's ballistic missile defense and has performed flawlessly in every test to date against every category of ballistic missile, and in raid scenarios."

The AN/TPY-2 radar Raytheon delivered will serve in terminal mode as the fire control radar for the U.S. Army's Terminal High Altitude Area Defense missile defense system. Other forward-based AN/TPY-2's that are deployed around the globe cue the BMDS by detecting, tracking and discriminating enemy ballistic missiles in the ascent phase of flight.

About AN/TPY-2

AN/TPY-2 is a high resolution, mobile, rapidly deployable X-band Radar capable of providing long-range acquisition, precision track and discrimination of all classes of ballistic missiles, from Short-Range Ballistic Missiles to Intercontinental Ballistic Missiles.

  • AN/TPY-2 has performed flawlessly in both terminal and forward-based mode in all major tests.
  • On Oct. 25, 2012, two AN/TPY-2 radars – one terminal and one forward-based – participated in FTI-01, the MDA's largest and most complex exercise. In a complex raid scenario involving multiple targets, both radars met or exceeded all test objectives.  
  • Forward-based AN/TPY-2's in Japan, Israel and Turkey are currently enabling the protection of the U.S., deployed troops, and U.S. friends and allies from the growing threat of short-, medium- and long-range missiles.

About Raytheon

Raytheon Company, with 2012 sales of $24 billion and 68,000 employees worldwide, is a technology and innovation leader specializing in defense, homeland security and other government markets throughout the world. With a history of innovation spanning 91 years, Raytheon provides state-of-the-art electronics, mission systems integration and other capabilities in the areas of sensing; effects; and command, control, communications and intelligence systems; as well as a broad range of mission support services.

Raytheon is headquartered in Waltham, Mass. For more about Raytheon, visit us at www.raytheon.com and follow us on Twitter @raytheon.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Raytheon Company. (2019, February 24). AN/TPY-2 - Mobile, X-band Phased-array Radar Helps Missile Defense Agency. AZoSensors. Retrieved on April 20, 2024 from https://www.azosensors.com/news.aspx?newsID=5679.

  • MLA

    Raytheon Company. "AN/TPY-2 - Mobile, X-band Phased-array Radar Helps Missile Defense Agency". AZoSensors. 20 April 2024. <https://www.azosensors.com/news.aspx?newsID=5679>.

  • Chicago

    Raytheon Company. "AN/TPY-2 - Mobile, X-band Phased-array Radar Helps Missile Defense Agency". AZoSensors. https://www.azosensors.com/news.aspx?newsID=5679. (accessed April 20, 2024).

  • Harvard

    Raytheon Company. 2019. AN/TPY-2 - Mobile, X-band Phased-array Radar Helps Missile Defense Agency. AZoSensors, viewed 20 April 2024, https://www.azosensors.com/news.aspx?newsID=5679.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.